ClinicalTrials.gg
CompletedNCT02268890Updated Jul 11, 2016

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

A Phase 4 interventional study of Bortezomib in Multiple Myeloma, sponsored by Johnson & Johnson Taiwan Ltd. Completed at 6 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-07-11.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
207th of 267
18 · median 41
Started
2014
with 9 others
Phase 4
8 of 271
1 open now
Registered
201st of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 207th largest by enrollment of the 267 interventional ones that give a count, is one of 10 that started in 2014, is one of 8 in phase 4, and was the 201st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetic (PK-the study of the way a drug enters and leaves the blood and tissues over time) characteristics of bortezomib when administered intravenously in Taiwanese participants with multiple myeloma (cancer of the types of cells normally found in bone marrow).

Read the detailed description

This is a Phase 4, single-arm, open-label (all knew the intervention of study), and multicenter (when more than 1 hospital or medical school team work on a medical research study) study to explore the pharmacokinetics with relapsed (the return of a medical problem) or refractory (not responding to treatment) multiple myeloma. The study consists of a Screening phase and a bortezomib treatment phase with defined PK sample collection time points. Participants will receive bortezomib intravenous injection two times a week up to 2 weeks (on Days 1, 4, 8, and 11) and followed by a 10-day resting phase (Days 12 to 21) for 1 treatment cycle. Pharmacokinetics will primarily be evaluated. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Bortezomib
  • Velcade
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma based on the standard criteria
  • Measurable, secretory multiple myeloma is defined as serum monoclonal immunoglobulin (Ig) G of >= 10 gram per liters (g/L), serum monoclonal IgA or IgE greater than or equal to (>=) 5 g/L, serum monoclonal IgD >= 0.5 g/L, or serum monoclonal IgM present (regardless of level), or urine M protein of >= 200 mg/24 hour at any time point of prior treatment
  • Relapse or progression of myeloma following prior systemic antineoplastic therapy and meet the indication which had been approved in the drug leaflet. Relapse is defined as: a) reappearance of (as defined above) following complete response (CR); b) >= 25 percent (%) increase in serum or urine M-protein according to IMWG (International Myeloma Working group) criteria; c) development of new or worsening lytic bone disease; d) new plasmacytomas or >=50% increase in the longest dimension of an existing plasmacytoma; e) worsening hypercalcemia (corrected serum calcium >11.5 milligram per deciliters [mg/dL-2.8 millimoles per liters [mmol/L] due to multiple myeloma
  • performance status >=70%
  • count >=50 × 10\^9 /L without transfusion support within 7 days before the laboratory test

Exclusion criteria

Exclusion Criteria:

  • More than 3 (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a >6 month treatment-free interval)
  • Peripheral neuropathy or neuropathic pain of National Cancer Institute- (NCI CTCAE) Version 4.03 Grade >=2
  • Any of the following within 3 weeks prior to enrollment in the study: antineoplastic or experimental therapy, use above 10 mg/day (prednisone or equivalent), or plasmapheresis
  • Any of the following within 2 weeks prior to enrollment in the study: radiation therapy, major surgery (kyphoplasty is not considered major surgery)
  • Prior other than multiple myeloma diagnosed or treated within the last 2 years, with the exception of completely resected carcinoma in situ or basal/squamous carcinoma of the skin
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Bortezomib

    Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.

    Drug: Bortezomib

Interventions

  • Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.

    Also known as: Velcade

06

What researchers measure

Primary outcomes

  1. Initial Observed Plasma Drug Concentration (Co)

    Initial concentration extrapolated to time zero (Co) will be evaluated.

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  2. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) will be observed.

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  3. Area Under Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Time Point

    Area under the plasma concentration-time curve from time 0 to the time of last quantifiable time point, calculated by linear trapezoidal summation.

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  4. Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity)

    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUClast + Clast/lamda(z), where Clast is the last measurable plasma concentration and lamda(z) is the terminal rate constant.

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  5. Terminal Half-life (t1/2)

    Terminal half-life, calculated by 0.693/lamda(z).

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  6. Terminal rate constant (lamda[z])

    Terminal rate constant estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  7. Systemic clearance (CL)

    Systemic clearance after IV dose, estimated by dividing the total administered dose by the plasma (AUC-Infinity).

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

  8. Apparent Volume of Distribution (Vd)

    Apparent volume of distribution (Vd) based on the terminal phase after intravenous administration, calculated as Dose/(Lamda\[z\] \* AUC-Infinity).

    Time frame: 72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14

07

Study locations

6 sites
  • Changhua, Taiwan
  • Kaohsiung, Taiwan
  • Taichung City, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2014
First posted
Oct 20, 2014
Start
Dec 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Jul 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02268890
Responsible party
Sponsor
First posted
Oct 20, 2014
Start date
Dec 2014
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Jul 11, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion